NO2909340T3 - - Google Patents

Info

Publication number
NO2909340T3
NO2909340T3 NO13789899A NO13789899A NO2909340T3 NO 2909340 T3 NO2909340 T3 NO 2909340T3 NO 13789899 A NO13789899 A NO 13789899A NO 13789899 A NO13789899 A NO 13789899A NO 2909340 T3 NO2909340 T3 NO 2909340T3
Authority
NO
Norway
Application number
NO13789899A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2909340T3 publication Critical patent/NO2909340T3/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241Tumor Necrosis Factors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
NO13789899A 2012-10-19 2013-10-18 NO2909340T3 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU1200607A HU230680B1 (hu) 2012-10-19 2012-10-19 Diagnosztikai eljárás
PCT/HU2013/000101 WO2014060785A2 (en) 2012-10-19 2013-10-18 DIAGNOSTIC METHOD FOR PREDICTING RESPONSE TO TNFα INHIBITOR

Publications (1)

Publication Number Publication Date
NO2909340T3 true NO2909340T3 (no) 2017-12-30

Family

ID=89990915

Family Applications (1)

Application Number Title Priority Date Filing Date
NO13789899A NO2909340T3 (no) 2012-10-19 2013-10-18

Country Status (12)

Country Link
US (1) US20160194709A1 (no)
EP (1) EP2909340B1 (no)
JP (1) JP2016502400A (no)
CA (1) CA2889087C (no)
DK (1) DK2909340T3 (no)
EA (1) EA037105B1 (no)
ES (1) ES2645972T3 (no)
HU (1) HU230680B1 (no)
NO (1) NO2909340T3 (no)
PL (1) PL2909340T3 (no)
UA (1) UA118658C2 (no)
WO (1) WO2014060785A2 (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016179469A1 (en) * 2015-05-07 2016-11-10 Abbvie Inc. Methods and compositions for diagnosing and treating inflammatory bowel disease
US10752699B2 (en) 2015-06-29 2020-08-25 Regents Of The University Of Minnesota Anti-APOBEC3 antibodies and methods of making and using
GB2547406A (en) * 2015-11-20 2017-08-23 Folkersen Lasse Apparatus and methods of using of biomarkers for predicting TNF-inhibitor response
GB201521357D0 (en) * 2015-12-03 2016-01-20 Univ Liverpool Methods for predicting response to anti-TNF therapy
US20190085405A1 (en) * 2016-03-23 2019-03-21 Regents Of The University Of Minnesota Methods of detecting apobec3 expression and predicting clinical outcomes
EP3755810A4 (en) * 2018-02-19 2022-03-23 Genefron Ltd. PROCEDURE FOR DETERMINING RESPONSE TO TNF-ALPHA BLOCKER
JP2021518432A (ja) 2018-03-16 2021-08-02 サイファー メディシン コーポレイション 抗tnf療法に対する応答性を予測するための方法及びシステム
KR102337232B1 (ko) * 2018-11-30 2021-12-09 차의과학대학교 산학협력단 뇌 유래 소포체 특이적 마커 및 이를 이용한 뇌 질병 진단 방법
JPWO2020116567A1 (ja) * 2018-12-07 2021-12-23 株式会社Dnaチップ研究所 関節リウマチ治療薬の奏効を予測する方法及びそれに用いるバイオマーカー
CA3145237A1 (en) 2019-06-27 2020-12-30 Scipher Medicine Corporation Developing classifiers for stratifying patients
KR102429261B1 (ko) * 2020-08-25 2022-08-03 충북대학교 산학협력단 한국인의 tnf 저해제 약물 반응성 예측을 위한 바이오마커

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3633000A (en) * 1999-03-26 2000-10-16 Human Genome Sciences, Inc. Neutrokine-alpha binding proteins and methods based thereon
CA2519870A1 (en) * 2003-04-09 2004-10-28 Genentech, Inc. Use of rituximab intravenous compositions to treat rheumatoid arthritis
EP1857559A1 (en) * 2006-05-16 2007-11-21 INSERM (Institut National de la Santé et de la Recherche Médicale) A method for predicting responsiveness to TNF alpha blocking agents
CN101711286A (zh) * 2007-04-02 2010-05-19 健泰科生物技术公司 预示类风湿性关节炎对b细胞拮抗剂的响应的生物学标志物
WO2008132176A2 (en) * 2007-04-27 2008-11-06 Universite Catholique De Louvain Method for evaluating the response of an individual to tnf blocking therapy
EP2679996A1 (en) * 2007-05-31 2014-01-01 AbbVie Inc. Biomarkers predictive of the responsiveness to TNF-alfa inhibitors in autoimmune disorders
EP2326731B1 (en) * 2008-08-25 2013-11-13 Janssen Biotech, Inc. Biomarkers for anti-tnf treatment in ulcerative colitis and related disorders
JP2011004743A (ja) * 2009-06-26 2011-01-13 Dna Chip Research Inc 関節リウマチ患者におけるインフリキシマブ薬効の有効性を判別する方法
WO2012061620A1 (en) * 2010-11-04 2012-05-10 Genentech, Inc. Methods for treating, diagnosing, and monitoring rheumatoid arthritis

Also Published As

Publication number Publication date
EP2909340B1 (en) 2017-08-02
WO2014060785A3 (en) 2014-06-12
UA118658C2 (uk) 2019-02-25
PL2909340T3 (pl) 2018-01-31
JP2016502400A (ja) 2016-01-28
WO2014060785A2 (en) 2014-04-24
ES2645972T3 (es) 2017-12-11
HU230680B1 (hu) 2017-08-28
CA2889087A1 (en) 2014-04-24
CA2889087C (en) 2021-11-16
EP2909340A2 (en) 2015-08-26
DK2909340T3 (da) 2017-11-13
EA037105B1 (ru) 2021-02-05
EA201590773A1 (ru) 2015-09-30
HUP1200607A2 (en) 2014-04-28
US20160194709A1 (en) 2016-07-07

Similar Documents

Publication Publication Date Title
BR112014017635A2 (no)
BR112014017614A2 (no)
BR112014017592A2 (no)
BR112014017625A2 (no)
BR112014017659A2 (no)
BR112014017646A2 (no)
BR112014017638A2 (no)
BR112014019610A2 (no)
AR092201A1 (no)
BR112014017607A2 (no)
BR112014022670A2 (no)
BR112014017634A2 (no)
BR112014017609A2 (no)
BR112014017673A2 (no)
BR112014017644A2 (no)
BR112014017647A2 (no)
BR112014017618A2 (no)
BR112014017652A2 (no)
BR112014025930A2 (no)
BR112014017621A2 (no)
BR112014017630A2 (no)
BR112014017627A2 (no)
BR112014017623A2 (no)
BR112014017622A2 (no)
BR112014017641A2 (no)